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Biology 
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Andrew G. Leach*[b] 
Dedicated to Prof. Dr. Jan B.F.N. Engberts on the occasion of 
his 80th birthday.  
Frontispiece text: When chemistry meets biology, as here with a 
child stumbling upon the enantiomers of cetirizine in the sea, 
stereochemistry often governs the outcome.  In aqueous 
environments, the process of racemisation will therefore be 
important and can be facilitated in a range of ways including by 
base, acid or enzymatic catalysis. The limited information 
concerning racemisation under each of these conditions is 
surveyed and critiqued. Tools to guide prediction of racemisation 
risk are presented. 
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Abstract: The two enantiomers of a compound often have 
profoundly different biological properties and so their liability to 
racemisation in aqueous solutions is an important piece of 
information.  We have reviewed the available data concerning the 
process of racemisation in vivo, in the presence biological 
molecules (e.g. racemase enzymes, serum albumin, cofactors 
and derivatives) and under purely chemical but aqueous 
conditions (acid, base and other aqueous systems). Mechanistic 
studies are described critically in light of reported kinetic data. The 
types of experimental measurement that can be used to 
effectively determine rate constants of racemisation in various 
conditions are discussed and the data they provide is summarised.   
The proposed origins of enzymatic racemisation are presented 
and suggest ways to promote the process that are different from 
processes taking place in bulk water.  Experimental and 
computational studies that provide understanding and 
quantitative predictions of racemisation risk are also presented. 
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Molecular symmetry, chirality and stereochemistry are defining 
concepts for organic chemistry. Appreciation of the relevance of 
chirality to many applications of molecules, particularly in 
biological systems, has been steadily growing over time. As a 
consequence, racemization has also become a subject of 
increasing concern. Although racemisation and related processes 
also occur in other media (See, e.g., the work by Blackmond on 
the origin of chirality which mainly focusses on enantiomerisation 
in solids), we here focus on racemisation in aqueous solutions 
and in particular under conditions with some resemblance to 
physiological conditions. 
 
Racemisation can be necessary and desirable. For instance, in 
biological systems, reductions in the levels of racemase activity 
and hence of D-Ser have been linked with the pathophysiology of 
Alzheimer’s disease.[1] Racemisation also underpins dynamic 
kinetic resolutions, which can be a very effective and efficient 
route to high yields of single enantiomers.[2,3] Racemisation of 
amino acids also allows dating of biological samples in amino acid 
dating.[4,5] However, racemisation is more often undesirable and 
has been linked with the formation of cataracts when proteins in 
the lens that are responsible for maintaining clarity undergo 
stereochemical scrambling and other transformations.[6,7] 
Racemisation can also cause what would otherwise be safe drugs 
to convert into toxic or ineffective forms.[8] As a consequence, the 
Food and Drug Administration (FDA) and other regulatory bodies 
require unambiguous data to be provided concerning the 
configurational stability of chiral drugs.[9,10] Racemisation may 
also feed into so-called “Chiral Pollution” by agrochemicals[11] and 
drugs.[12] 
 
It has become clear to us over recent years that there have been 
significant steps forward in our knowledge about, and 
understanding of, racemisation in several arenas and we wish to 
draw these together to provide an overview of the strategies for 
employing or avoiding racemisation used by chemists and by 
nature. It is however also clear that the scope of these studies 
remains narrow and the evidence base smaller than is required 
for a full understanding, both in terms of available kinetic data and 
mechanistic studies. In this light, we have attempted to provide a 
comprehensive critical review of the available studies in order to 
provide a stimulus to others to expand our knowledge. It is also 
hoped that, by describing (in less depth) some of the key ideas 
about racemisation in biology, we will promote the transfer of 
ideas between chemical and biological sciences. Finally, we are 
also keen to address an attitudinal problem that we have 
encountered too frequently amongst chemists; because it is easy 
to post-rationalise a racemisation problem using the concepts of 
physical organic chemistry, this does not mean that chemists are 
reliable at predicting these problems in advance. We hope that 
this review will highlight some of the interesting and challenging 
problems that chemists should look out for and provide guidance 
on how to address these challenges. 
 
a) Racemisation and enantiomerisation 
 
Racemisation is a statistical, macroscopic and irreversible 
process in which half of an enantiopure quantity of compound is 
transformed into the opposing enantiomer (Scheme 1, top). It is 
complete when the enantiomeric excess (e.e.) of the sample 















Scheme 1. Top: The process of racemisation. Bottom: The 
process of enantiomerisation. 
 
Racemisation clearly has to be a macroscopic process because 
racemisation of a single molecule is impossible. Nevertheless, it 
is useful to consider the link between microscopic (molecular) 
processes and macroscopic racemisation. For cases where 
chirality is based on a stereogenic carbon atom, the molecular 
processes leading to racemisation often involve formation of an 
achiral carbocation, an achiral carbanion intermediate or an 
achiral free radical. Subsequent non-enantiospecific reformation 
of the stereogenic centre then leads to a racemic mixture. One 
could call this type of process “racemisation by loss of 
enantiomeric memory”. Typical molecular processes of this kind 
that lead to macroscopic racemisation are discussed in Sections 
2d and 2i. 
 
Enantiomerisation is also related to racemisation but is a 
microscopic process involving reversible conversion of one 
molecule of an enantiomer into its mirror image (Scheme 1, 
bottom). Repeated enantiomerisation eventually results in 
racemisation. It is often said that enantiomerisation of one 
molecule effectively reduces the e.e. of the whole system by two 
molecules and therefore the rate constant for racemisation is 
twice that of enantiomerisation. More precisely, for a system 
undergoing enantiomerisation, the observed rate constant krac for 
approaching the dynamic equilibrium (that is the racemic mixture) 
is the sum of the two mechanistic rate constants kenant that 
together define the corresponding equilibrium constant of 1.[13] 
For the example in Scheme 1, the rate constant for racemisation 
krac is therefore 2 x kenant.  
 
Under certain conditions, racemisation through loss of 
enantiomeric memory and racemisation resulting from repeated 
enantiomerisation can therefore be distinguished because the 
rate constant for racemisation is either equal to or exactly double 
the rate constant for the underlying process (See, e.g., Section 
2c). 
 
Many compounds have more than one stereogenic center in them. 
In these molecules, the formal process of racemisation involves 
the inversion of all of the stereocenters. Such molecules are more 
likely to undergo the related process of diastereoisomerisation or 
epimerisation in which not all of the stereogenic centers invert. An 
example of epimerisation is provided by studies of RS10085.[16] 
The process of epimerisation will not be discussed in this article.  
 
b) Why is racemisation important for drug discovery? 
 
Racemisation would only be important if two enantiomers have 
biological properties that differ enough to cause measurably 
different effects in complex biological systems such as a human 
being. Recent large-scale surveys of measured data have 
therefore sought to identify which biological properties are most 
strongly influenced by inversion of chirality. The measured 
differences between enantiomers in the Astrazeneca and 
Novartis company databases were analysed by two different 
statistical approaches (both attempting to distinguish the 
additional variation between enantiomers from the natural 
variation between repeat measurements).[17,18] The results of the 
two surveys are summarized in Table 1. As expected, solubility 
and logD are unaffected by inversion of stereochemistry. 
Somewhat surprisingly, given their cellular basis and the 
involvement of active uptake and efflux processes, the 
permeability assays (Caco2 and MDCK) do not show a difference 
between enantiomers. This general lack of sensitivity in 
permeability is supported by studies investigating trans-dermal 
delivery of ketoprofen which found no measurable difference 
between the enantiomers or racemate.[19] The lack of 
discrimination between enantiomers for the active processes is in 
line with recent structural findings suggesting that P-glycoprotein 
efflux transporter PGp presents a large open (undiscriminating) 
cavity to the cell interior into which substrates can move. This 
cavity then rearranges to extrude the substrates from a much 
more constrained cavity towards the cell exterior.[20]  
 
On the other hand, metabolism and in vivo pharmacokinetics are 
influenced by chirality. Inhibition of most of the cytochrome P450 
isoforms is also strongly influenced by the stereochemistry with 
the exception of isoform 3A4. Isoform 3A4 has a markedly weaker 
dependence and this likely reflects the fact that 3A4 is another 
system that employs a large, open and flexible cavity.[21] 
 
Table 1. A range of biological properties of molecules and the 
degree to which they are affected by inversion of 
stereochemistry.[17,18] 
Property Astrazeneca dataa Novartis datab 
Solubility - - 
















CYP 1A2 inhibition ++ n.m. 
CYP 2C9 inhibition ++ n.m. 
CYP 2C19 inhibition +++ n.m. 
CYP 2D6 inhibition +++ n.m. 
CYP 3A4 inhibition + - 
Field Code Changed




















a) The variance due to chiral inversion has been categorised as - 
= 0; + = <0.02; ++ = 0.02-0.1; +++ = >0.1. b) - = p>0.05. For cases 
where the p-value is less than 0.05, the Kolmogorov-Smirnov D 
values have been categorised as + = <0.1; ++ = 0.1-0.4; +++ = 
>0.4. n.m. = not measured. 
 
The differences in properties extend to those molecules that 
contain chiral axes instead of stereogenic centres. In a recent 
report, the P atropisomer of the phosphoinositide 3-kinase 
inhibitor 1 was found to be a markedly better inhibitor than its 
enantiomeric alternative (the M atropisomer).[22] In addition, 1 has 
a lower in vitro clearance than its enantiomer in tests using human 
hepatocytes or microsomes; its enantiomer is particularly liable to 




The consequences of the differences in medicinal chemistry 
properties of enantiomers are nicely demonstrated through the 
resulting differences in pharmacokinetics aas studied in detail for 
2 and 3. A study of the plasma concentration-time curves for 
ketorolac (3) revealed markedly different profiles for the two 
enantiomers following intravenous injection of racemate to 
healthy volunteers.[24] The in vivo clearance of S-3 was found to 
be 10.99 L min-1 while that for R-3 is 3.24 L min-1. This leads to 
higher concentrations of R-3 being achieved. 
  
The importance of racemisation for specific drugs has also been 
emphasised in a review that details the properties of drugs and 
their enantiomers.[25] While many have enantiomers that are 
viewed as inactive, some have toxic or dangerous enantiomers. 
In both cases, racemisation is harmful either by reducing the dose 
of active compound or by leading to exposure to harmful 
compounds even when only the safer enantiomer has been taken. 
 
Racemisation is also important in drug discovery because it can 
determine whether chiral switching is likely to be an economically 
attractive proposition. Chiral switching is when an improved single 
enantiomer (with ongoing patent protection) replaces a racemate 
(whose patent protection is expired). A marketing case for the 
single enantiomer is unlikely to be viable if it rapidly racemises. 
By way of example, a detailed package of studies was undertaken 
to understand the effect of switching the selective H1-receptor 
antagonist racemic cetirizine (2) to a single enantiomer, 
levocetirizine (L-2). A decision tree was proposed in which the 
differences between the pharmacokinetics, pharmacodynamics, 
interactions with other drugs and rate of racemisation are all 
considered.[23] L-2 has a higher apparent affinity for the H1 
receptor and similar pharmacokinetics to the racemate (and the 
enantiomer dextrocetirizine). When healthy volunteers were given 
doses of either 2.5 mg of L-2 or 5 mg of racemic 2, after 32 hours 
those who had taken L-2 still had a measurable benefit while 
those who took the racemate did not. Following dosing with 
levocetirizine, none of the enantiomer dextrocetirizine was found 
in urine supporting a lack of in vivo racemisation (in line with 
results in pH 7.4 buffer and in plasma). The authors advocated for 
a change from racemate to single enantiomer based on this 
extensive package of data. This example highlights the non-linear 
effects of dosing mixtures of compounds such as racemates and 
Table 1 shows that this can arise through changes in a wide range 
of biological properties that combine in ways that make the 
prediction of human pharmacokinetics and pharmacodynamics 
extremely challenging. 
 
In an approach opposite to a chiral switch, one could imagine that 
administering the racemate of a rapidly racemising drug could 
lead to naturally enriching the drug as the required enantiomer as 
a result of selective binding to the target (Cf. dynamic kinetic 
resolution). Unfortunately, the mass balance of drug-target 
interactions typically involves a large systemic excess of the drug 
relative to the target, meaning that this approach is unlikely to be 
efficient. 
 
For the reasons above, racemisation is important in drug 
discovery. This fact is further highlighted by the link between 
racemisation risk and failure in clinical trials. When quantitative 
calculations (described below) are applied to identify molecules 
that are at risk of racemisation, it was found that such molecules 
are less likely than others to proceed from one stage of clinical 
trials to the next.[26] This is despite the known trend for molecules 
with a chiral centre to be more likely to succeed than those that 
lack one.[27]  
2. Kinetics and mechanisms of racemisation 
In this article, we limit discussion to mechanisms that are relevant 
in aqueous media; this precludes some possibilities and 
introduces others, as will be discussed below. Racemisation in 
aqueous conditions is subject to a number of influences, 
particularly acid or base catalysis, either of which might be 
general or specific. The observed rate laws form kinetic 
signatures for the possible reaction mechanisms (Figure 1). 
 







Figure 1. Typical reaction mechanisms for the different rate laws 
for acid and base catalysis.  
 
In compiling this review, it has become clear that the mechanistic 
details of the racemization of some molecules has been 
inadequately or incorrectly classified, despite the long-accepted 
links between rate laws and mechanisms shown in Figure 1. We 
therefore provide some critical descriptions of many of these, 
describing first reactions subject to acid catalysis and then those 
subject to base catalysis. Finally, racemisation via other 
mechanisms or uncharacterised processes is described. 
 
 
a) Mechanisms of racemisation giving rise to acid catalysis 
 
Stereogenic carbons bearing a hydroxyl group have the possibility 
of specific- or general-acid catalysed racemisation. Protonation of 
a hydroxyl group enhances its ability as a leaving group, allowing 
it to depart leaving behind a carbocation (Scheme 2). Protonation 
in these cases is typically an equilibrium process before the rate-
determining step, resulting in a specific-acid-catalysis rate law. 
The carbocation can be trapped by water, reintroducing a 
hydroxyl group. Systems in which the carbocation is stabilised are 
most likely to undergo this type of reaction. Certain molecules also 
contain nucleophilic groups that can 1) trap the carbocation in an 
SN1 fashion which would lead to racemisation of the stereogenic 
center once the trapping group leaves and water returns to 
reintroduce the hydroxyl or 2) directly displace the protonated OH 
which would lead ultimately to retention of stereochemistry upon 
readdition of water.  
 
In aqueous solutions, protonation of groups other than hydroxyl 
can only lead to racemisation if the carbocation and leaving group 
are held within the solvent cage so that they can reform a bond 
more quickly than the carbocation is intercepted by water. For 
racemisation to occur, the reaction must proceed in a way that 
nevertheless permits the group that left to attack either face of the 
carbocation. In general this is unlikely (See Section 2.f.iii), but the 
case of stereocenters in ring systems is a special one because 
the group that leaves can remain part of the molecule and can 
therefore react intramolecularly (Scheme 2). 
 
Scheme 2. Generic mechanisms for acid catalysed racemisation. 
 
The examples above typically result in specific-acid-catalysis rate 
laws. General-acid catalysis occurs less frequently (See Table 5) 
because racemisation involving rate-determining protonation or 
involving acid-assisted nucleophilic attack are less likely. We note, 
however, that a mechanism involving equilibrium protonation 
followed by rate-determining deprotonation at a different site will 
also give rise to a general-acid catalysis rate law. This type of 
behaviour is anticipated, e.g., at neutral pH for stereogenic 
centres adjacent to carboxylates or next to amines with a pKa 
below 7 (Scheme 3).  
 
 
Scheme 3. Generic mechanism involving equilibrium protonation 
followed by rate-determining deprotonation at a different site 
leading to a general-acid catalysis rate law 
 
b) Examples of racemisation reactions displaying acid 
catalysis 
 
We here review aqueous racemisation reactions for which kinetic 
data indicate acid catalysis, separating the examples into those 
showing specific-acid catalysis and those showing general-acid 
catalysis. 
 
i) Specific-acid catalysis 
 
A good example of the acid-catalysed racemisation of a hydroxyl 
group is provided by the racemisation of catecholamines such as 
adrenaline (4, Scheme 4) in 1.0 M hydrochloric acid. Here the 
carbocation intermediate is significantly stabilised by the adjacent 
electron-rich aromatic ring which is required to overcome the 
destabilisation of the positive charge resulting from the adjacent 
ammonium cation.[28] For comparison, 1-phenylethanol 
racemises slightly faster than 4. Removal of the π-electron 
donating p-OH slows down the racemisation by three orders of 
magnitude. 
Scheme 4. Racemisation of 4. 
 






The anti-arrhythmic Ibutilide (5, Scheme 5) can also undergo 
racemization via formation of a carbocation. The alternative direct 
intramolecular displacement of the protonated hydroxyl group by 
the amine would give a cyclic intermediate with inversion that 
would in turn be subject to attack by water yielding the alcohol in 
its original configuration. It has been shown that both racemisation 
and formation of the cyclic ammonium ion proceed via the 
carbocation, but that racemisation through repeated 
enantiomerisation resulting from direct attack of water on the 
stereogenic centre plays an important role as well.[29] 
 
Scheme 5. Racemisation of 5. 
 
ii) General-acid catalysis 
 
An example of reactions going through the general-acid catalysis 
rate law as a result of a mechanism involving equilibrium 
protonation followed by rate-limiting deprotonation elsewhere is 
presented by tautomerisation reactions, such as shown in 
Scheme 6. [30]  
 
Scheme 6. Acid catalysis of racemisation via tautomerisation. 
 
Racemisation of 9-hydroxyrisperidone 6 is a specific example of 
this type of reactivity. Compound 6 could undergo acid-catalysed 
racemisation via protonation and elimination of the alcohol or via 
protonation at nitrogen (Scheme 7).[31] The latter was proposed 
as the most likely route for racemisation because of the electron-
withdrawing groups adjacent to the carbocation that would form if 
the alcohol were to leave. 
 
Scheme 7. Racemisation of 6. 
 
c) Mechanisms of racemisation giving rise to base catalysis 
 
A common base-catalysed racemisation process is one in which 
a stereocenter of type R1R2R3CH is deprotonated to yield a flat 
anion (Scheme 8). This anion can then reprotonate from either 
face.  
 
Scheme 8. General mechanism of base-catalysed racemisation. 
 
The details of the deprotonation and reprotonation can 
significantly influence the outcome and at the extremes can lead 
to racemisation, enantiomerisation or indeed retention of 
configuration as demonstrated by Cram et al., albeit not in 
aqueous solutions.[32] 
 
These reactions can be illuminated by investigating the rate at 
which the proton at the stereocenter is exchanged for a deuterium 
if the reaction is performed in deuterated buffers (or deuterium 
with proton if starting with a deuterated molecule). There are four 
contrasting scenarios for the rate constants for deuteration kdeut 
and for racemisation krac: 
 
kdeut/krac is 1 when a purely racemising process takes place and 
deuteration occurs equally on both faces of an intermediate anion. 
This involves an SE1 mechanism in which deprotonation leads to 
a planar carbanion, with complete separation of the departing 
proton (i.e. the proton is not retained inside the solvent shell ready 
to reprotonate). There are many structural features that can 
stabilise or destabilise these carbanionic intermediates and these 
are discussed below. 
 
 kdeut/krac is 0.5 when the process takes place exclusively with 
inversion. This involves an SE2 mechanism in which 
deprotonation occurs on one face of the stereogenic carbon with 
simultaneous reprotonation on the opposite face. This push-pull 
mechanism involves a greater preorganisation and therefore 
entropic barrier than the SE1 mechanism. Many of the groups that 
stabilise carbanions and therefore facilitate the SE1 mechanism 
can also facilitate the SE2; the transition state for this reaction 
involves significant anionic character at the stereogenic center.  
 
kdeut/krac tends to infinity if the process takes place exclusively with 
retention (deuteration takes place but there is no stereochemical 
scrambling) 
 
kdeut/krac tends to zero when racemisation takes place with no 
deuteration, in which case a mechanism not involving proton 
transfer is in operation. 
 
Specific-base catalysis is less likely because loss of proton often 
leads to immediate loss of chirality, apart from for examples such 
as the deprotonation of a hydroxide in molecules such as 
chlortalidone (7, Scheme 12) where the deprotonated form then 
undergoes fragmentation leading to an achiral intermediate. 
 
d) Examples of racemisation reactions displaying base 
catalysis 
 
As for acid catalysis above, we review aqueous racemisation 
reactions for which kinetic data indicate base catalysis, separating 
the examples into those showing specific-base catalysis and 
those showing general-base catalysis. 
 
i) Specific-base catalysis 
 






As mentioned above, specific-base catalysis is likely to be less 
common than general-base catalysis. Examples do, however, 
occur. 
 
A loss of chiral purity was observed for the Eg5 inhibitor R-
litronesib (8) during storage in a liquid formulation.[33] This 
racemisation is base-catalysed, despite the stereogenic centre 
being quaternary. Studies revealed that the racemisation 
depends on pH but does not depend on buffer identity, i.e. 
specific-base catalysis. On the basis of this observation, a 
mechanism involving equilibrium deprotonation of the 
sulphonamide was proposed which is followed by a multi-step 
ylid-mediated process featuring a relay of ionized groups 
(Scheme 9).  
 
 
Scheme 9. Racemisation of 8. 
 
ii) General-base catalysis 
 
An important discussion for racemisation involving general base 
catalysis is whether the reaction proceeds through the SE1 or the 
SE2 mechanism. There are two cases in which the SE2 process 
has been proposed. The first case is the racemisation of some 5-
substituted hydantoins (9) for which an observed kdeut/krac of 0.5 






Table 2. Rate constants of H/D exchange and racemisation of 
hydantoins (9).[34] 
R  kdeut (h-1)a  krac (h-1)a  krac (h-1)b 
Ph  11.3  21.1  23.7 
CH2Ph  0.060  0.094  0.119 
a determined in a mixture of D2O phosphate buffer (pD 7.4, 
0.1M, I = 0.22) and (d6)DMSO in proportion 1:1 (v/v) at 50 °C. 
b determined in a mixture of phosphate buffer (pH 7.4, 0.1M, I 
= 0.22) and DMSO in proportion 1:1 (v/v) at 50 °C 
 
We note that the ratio kdeut/krac of 0.5 was found when comparing 
deuterated with non-deuterated buffer and that the ratio kdeut/krac 
is different when comparing racemisation and deuteration in the 
same deuterated buffer. Taken together with results from other 
studies this casts doubt on whether the SE2 mechanism is really 
active here, leaving the SE1 mechanism as the most likely 
mechanism.[35–37] 
 
The second case involves the fast racemisation of thiohydantoin 
10 which under acidic conditions has also been proposed to occur 
via an SE2 mechanism on the basis of a comparison between rate 
constants for racemisation and deuteration (Scheme 10).[37] 
 
 
Scheme 10. Racemisation of thiohydantoin 10. 
 
Amfepramone (11, Table 4) racemisation rates were measured 
over a pH range of 5.5 to 8 and with varying phosphate buffer 
concentrations (as well as in human plasma).[38] Racemisation 
rate constants increased with increasing pH and with increasing 
buffer concentrations, but neither increase was linear. There is no 
obvious site for equilibrium deprotonation, making general-base 
catalysis resulting from rate-determining deprotonation the most 
likely mechanism for racemisation. This interpretation does not 
explain the non-linear behaviour, however. Compound 11 might 
also undergo equilibrium protonation on the nitrogen, followed by 
rate-determining deprotonation of the stereogenic centre. This 
mechanism can be ruled out in the pH range studied because 
general-acid catalysis was not observed.  
 
Rate-determining deprotonation has also been proposed for 
racemisation of the fungicide agrochemical triadimefon (12).[39] 
Although buffer concentrations were not varied and general-base 
catalysis was therefore not proven, the site of H/D exchange, the 




e) Reactions displaying both acid and base catalysis 
 
When racemisation is studied over a wide range of pH, substrates 
often display pH-dependent racemisation mechanisms, 
potentially combining acid catalysis, base catalysis and 
uncatalysed racemisation. For systems displaying both acid and 
base catalysis but no uncatalysed reaction, a V-shaped pH-rate 
profile is found. For systems displaying acid catalysis, 
uncatalysed reaction and base-catalysed reaction, a U-shaped 






pH-rate profile is found. Example compounds for which multiple 
catalytic regimes have been identified are reviewed here. 
 
The pain medication ketorolac (3) was studied at 80 °C in a range 
of buffers with pHs spanning 1 to 11.[40] A U-shaped pH-rate curve 
(Figure 2) suggests maximum stability at intermediate pHs and 
supports both acid and base catalysed racemization. The pH-
independent region extends from pH 2 to 8 and remarkably, 





Figure 2. pH-rate profile for racemisation of ketorolac at 80 °C 
(Reproduced using data from Ref. [40]) 
 
Working at pH > 3.5, the authors observed general-acid catalysis 
when using buffers involving anionic bases but general-base 
catalysis when using the neutral base tromethamine (better 
known as TRIS). The authors attributed these observations to 
neutral bases not experiencing electrostatic repulsion with the 
carboxylate group, leading to general-base catalysis (Scheme 
11a) and general-acid catalysis for anionic bases (Scheme 11b). 
We propose an alternative mechanism, involving equilibrium 
protonation of the carboxylate followed by rate-determining 
deprotonation of the stereogenic centre (Scheme 11c) which 
would similarly lead to a general-acid catalysis rate law. This 
proposal also explains why formate buffer can act either as 
general-acid or general-base catalyst depending on the pH at 
which the reaction is studied; at low pH, 3 is fully protonated so 
equilibrium protonation no longer plays a role and the rate law 




Scheme 11. Racemisation of 3.  
 
Chlortalidone, 7, has both acid and base-catalysed routes of 
racemisation open to it (Scheme 12).[41] This leads to a V-shaped 
pH-rate curve for racemisation (Figure 3). 
 
 
Figure 3. Dependence of rate constant of racemisation of 7 on 
pH (Reproduced using data reported in Ref. [41]) 
 
Under acidic conditions, the reaction is proposed to proceed via a 
carbocation that can add water. This cationic intermediate can 
also lead to formation of an imine.[42] The base-catalysed 
mechanism for racemisation is proposed to involve the hydroxyl 
group being deprotonated, promoting the fragmentation of the 
adjoining C-N bond, thereby opening the ring. The ring-opened 
form is stabilised by formation of a carbonyl and delocalised anion. 
The ring can then reclose via attack on either face of the carbonyl 
in the ring-opened form. The proposed mechanisms are 
reasonable and should result in specific-acid and specific-base 
catalysis rate laws. The literature does not report data for different 
buffer concentrations, so these expected rate laws cannot be 
confirmed. 






























Scheme 12. Racemisation of 7 under acid- or base-catalysed 
conditions. 
 
Several mechanisms for racemisation of oxazepam (13) have 
been proposed, including formation of an achiral ring-opened 
iminoaldehyde form (Scheme 13) from protonated 13. [43] Kinetic 
data,[44,45] however, show that racemisation of 13 is inhibited at 
low pH, display a wide pH-independent range which does not 
involve general-acid catalysis, and a hydroxide-catalysed regime 
which ends in a plateau, attributed to depronated oxazepam not 
being a good substrate for hydroxide-catalysed deprotonation. 
Similarly, 13 (Scheme 13) can undergo base-catalysed 
racemisation via deprotonation, ring opening and ring 
reclosing.[45] This mechanism would give rise to a specific-base 
catalysis rate law, as observed. We note, however, the 
occurrence of kinetic equivalence between neutral 13 reacting 
with hydroxide (kOH × [OH-]) and deprotonated 13 reacting via an 
alternative mechanism (kO-). Scheme 13 is in agreement with the 
kinetic data, and with previously determined pKa values,[46] but 
does not explain by which mechanism racemisation of neutral 13 
occurs. 
 
Scheme 13. Racemisation of 13 under acid- or base-catalysed 
conditions. 
 
Meluadrine (14, Scheme 14) undergoes racemisation with a 
complex dependence on pH (Figure 4).[47] The reaction was 
studied at a range of pHs and temperatures and this permitted 
fitting a model to the data to obtain values for the dissociation 
constants for the phenol and amine and to compute rate constants 
for the racemisation of each of the species and finally to obtain 
activation energies that were in the 23 – 27 kcal/mol range. The 
range of possible mechanisms for racemisation (Scheme 14) is 
consistent with the observed variation of rate constants and, at 
low pH, the mechanism is analogous to the data and mechanism 




Figure 4. pH dependence of the rate constant for racemisation of 
14 at 40 °C, simulated using the rate constants as reported.[47,48] 
 
 
Scheme 14. Racemisation of 14. 
 
The rate of racemisation of mandelic acid (15¸ Table 5) was found 
to be faster than that for deuterium incorporation in D2O under 
















acid conditions and this was attributed to the reaction proceeding 
via acid-catalysed dehydration.[49] At higher pHs, the two 
processes proceed at the same rate and therefore share the enol 
form as a common intermediate. 
 
Thiazolinedione 16 (Table 4) is particularly sensitive to 
racemisation, even racemising in ethanol-hexane eluents during 
HPLC.[50] In aqueous solutions, a non-linear relationship with pH 
was found for the racemisation rate of related pioglitazone 17 
(Table 4),[51] with the reaction proceeding faster at higher pH. 
The data suggest the reaction is subject to base-catalysed 
racemisation. The effect of buffer concentration was not studied 
for these compounds, but it is likely that base-catalysed 
racemisation proceeds via general-base catalysis forming an 
anion (likely of an aromatic type) in the rate-determining step. The 
observation by Welch et al. that racemisation in aqueous solutions 
cannot be stopped with addition of acid might suggest that 16 can 
also racemise via ring-opening in an acid-catalysed fashion.[50] 
 
f) Other mechanisms 
 
There are several other mechanisms by which compounds can 




Tautomerism can provide a low energy alternative to either a 
carbocation or carbanion. Translation of protons around a 
molecule may involve exchange with the solvent or direct transfer 
and can be acid or base catalysed, as shown for 6. Ring chain 
tautomerism, as exemplified by the racemisation of 13, is also a 
viable mechanism for racemisation. Tautomers and racemising 
enantiomers are both challenging problems for those trying to 
generate electronic representations of chemical structures, such 
as SMILES strings.[52] When placed in water, exchange between 
tautomeric forms is often facile and involves the molecule rapidly 
exchanging between forms that have different connectivity 
between the atoms, each of which would be represented by a 
different structural representation.  The same problem occurs for 
molecules that can rapidly racemise; the two enantiomers can be 
represented by a different SMILES string. When considering 
interactions with a protein, both stereoisomers must be generated 
and evaluated, just as all tautomers must, regardless of which 
structural representation is provided as input by the user.  
 
 
ii) Latent symmetry 
 
There are some molecules that can undergo racemisation or 
enantiomerisation when the group that is exchanged is neither 
proton nor hydroxyl (the groups available in water). They can do 
this when the group that is exchanged is present in the molecule 
already. An example is provided by the molecule allantoin (18, 
Scheme 15) in which the attack of the NH2 of the acyclic urea on 
the amide carbonyl can lead to urea exchange, which also 
corresponds to racemisation through repeated enantiomerisation. 
 
 
Scheme 15. Racemisation of 18. 
 
 
iii) Racemisation through heterolysis 
 
A mechanistic probe of carbocation-mediated racemisation 
involving a leaving goup that is not hydroxide was provided by 
studies of the racemisation and solvolysis of the 
pentafluorobenzoate 19 in 50:50 (v/v) trifluoroethanol-water 
(Scheme 16).[53] This racemisation is presumed to proceed 
through the loss of the benzoate to form an ion pair involving 
carbocation 20 and the pentafluorobenzoate anion. The ion pair 
can either separate to form free ions, be intercepted by solvent or 
return to the starting material. If returning to starting material, in 
principle, the benzoate could attack each face with equal 
probability leading to racemisation. However, it was found that the 
microscopic rate constant for racemisation is actually six times 
lower than for 18O scrambling and very similar to the microscopic 
rate constant for separation to free ions. These observations 
indicate that, most of the time, when the benzoate counterion 
does reform a bond to the carbocation, it does so with retention. 
This supports a view in which the ion pair intermediate in the 
solvent cage is held together quite rigidly and so attack from the 
two faces of the carbocation is not equally likely. 
 
 
Scheme 16. Racemisation of 19. 
 
 
iv) Rotation about single bonds 
 
Molecules that have resolvable enantiomers by virtue of hindered 
rotation about single bonds undergo racemisation when rotation 
around that bond occurs. This type of racemisation is intimately 
related to atropisomerism and has been studied 
computationally.[15,54] Calculations on 1 using the MMFF force 
field and at the B3LYP/6-31G** level complemented variable 
temperature NMR measurements that suggest a barrier to 
rotation of 35 kcal/mol.[22] Removal of the methyl on the imidazole 
ring was computed to lower the barrier to about 17 kcal/mol 
consistent with the observation of free rotation. Another combined 
experimental and computational study of 21 and 22 revealed the 
significant effect of ring expansion on racemisation rate (Table 
3).[55] 
 
Table 3. Computeda and measured barriers and half lives for 
racemisation of 21 and 22.[55] 






R Computed barrier 
(kcal/mol) 
Experimental t1/2 (s) 
 21 22 21 22 
H 16.9 20.5 0.2 1 x 102 







Tan and Paton have shown that the hole-catalyzed racemization 
of atropisomeric biaryls occurs via a two-step mechanism in a 
process controlled by frontier molecular orbitals.[56]  
 
v) Mechanism not known 
 
The stereochemical scrambling of vitamin C (23) was detected 
upon storage (in this case, the enantiomer is presumed to be 
biologically inert and to be rapidly excreted).[57] The process of 
racemisation was monitored through measurement of optical 
rotation. This showed that the rotation decreased from 25.55°C to 
0°C over the course of 63 days stirring at room temperature (or 6 
days at 80-90°C). This observation supported either complete 
racemisation or degradation to an achiral product (Scheme 17). 
NMR and IR analysis combined with quantum mechanical 
calculations supported the reactions shown. 
 
 
Scheme 17. Racemisation of 23. 
 
The racemisation of 24, which occurs alongside hydrolysis, was 
studied using a triple-column HPLC technique.[58] The hydrolysis 
product is only observed at low pH. A common ring-opened 
intermediate for the two processes was proposed (Scheme 18). 
 
 
Scheme 18. Racemisation of 24. 
 
For epimerisation of related compound 25, the same research 
group proposed a slightly more elaborate pH-dependent 
mechanism (Scheme 19).[59] 
 
 
Scheme 19. Epimerisation of 25. 
 
This mechanism does not explicitly demonstrate the protonation 
and deprotonation processes. The proposed intermediate is in 
agreement with the observation that methylation of the 
sulfonamide-N in this class of compounds leads to inhibition of 
racemisation at neutral to high pH and an acid-catalysis rate 
law.[60] The mechanism is also in line with the observation of a 
lack of H/D exchange on the stereogenic centre in 50-50 CD3OD-
D2O which indicates that there must be at least one pathway to 
racemisation that does not involve deprotonation of the 
stereogenic centre.[61] In general, the kinetics for racemisation 
for this class of compounds do not show a clear pH 
dependence.[58,61,62] The effects of changes in buffer 
concentration were not studied. In addition, there is a potential 
discrepancy between these data and the data published by 
Blaschke and co-worker whose kinetic data show a far stronger 
pH dependence of this reaction, potentially suggesting a specific-
base catalysis rate law.[63] As a result, there is currently 
insufficient data to conclude with certainty what the detailed 
mechanism of racemisation is. 
 
Similarly, a non-fragmenting quaternary ammonium ionization tag 
for mass spectrometric sequencing of peptides, based on the N-
spiro proline residue (26), was found to quickly racemise and 
undergo H/D-exchange in 1% trimethylamine in D2O.[64] 
 
 
No kinetic data were reported, but it is likely that this reaction 
proceeds via general-base catalysis. 
 
g) Racemisation of nicotine under pyrolysis conditions 
 
Although most biological racemisations take place in aqueous 
conditions, the racemisation of one molecule (nicotine, 27) under 
extreme heating and in the vapour phase has received a great 
deal of attention. In normal tobacco, 27 is predominantly the S 
enantiomer with estimates ranging from 0.03 % to about 0.2 to 
0.3 % of R-27 present.[65–67] However, in tobacco smoke, this 






increases to about 3%. The variation between tobacco types was 
studied by GCMS and it was found that the R enantiomer was 
consistently below 0.5 % of total 27 in eight different brands and 
then 2.6 – 3.6 % in the smoke. Subsequent pyrolysis of S-27 
revealed that it is stable up to about 400°C and that 
decomposition, including racemization, occurred in the 450 to 
550 °C range and up to 22 % of R was detected at the top of this 
temperature range. A similar effect occurred when tobacco was 
pyrolysed. It was suggested that a burning cigarette will contain 
zones at varying temperatures, with those adjacent to the burning 
area being in the 200 to 600°C range, enough to drive the 
observed racemization. Others have supported this view.[68] The 
racemization is presumed to proceed via homolysis of the CH 
bond at the stereogenic centre leading to a planar radical. Other 
studies had shown that when pure S-27 is pyrolysed up to 1000°C 
that no R-27 is observed, suggesting that the racemization in 
tobacco may rely on other material that is present in the 
tobacco.[69] It is likely that the heterogeneity of tobacco accounts 
for much of the divergence between measured amounts of 
racemisation in each of the samples studied. 
 
 
h) Racemisation in dynamic kinetic resolution 
 
Methods have been developed that permit the stereoselective 
transformation of one enantiomer present in a mixture of 
enantiomers. This process is intrinsically inefficient because even 
if it works perfectly, any of the other enantiomer remains as waste. 
One way to avoid this waste is to simultaneously facilitate 
racemisation of the starting material. In this way, all of the material 
can be funnelled through the desired reaction and can yield one 
stereoisomer exclusively. This is dynamic kinetic resolution and is 
one of the situations in which racemisation is desirable.[2,3,19,70] 
If working with amino acids, efficiently racemising derivatives 
include: hydantoins, oxazolones and thioesters.[71] The topic has 
been reviewed elsewhere and here a few of the more recent and 
relevant publications are described, particularly those that have 
sought to understand the racemisation process. These 
resolutions often use enzymes in which case the racemization has 
to be compatible with predominantly aqueous solutions. 
 
In a combined experimental and computational study, the 
computed deprotonation energies of N-protected thioester amino 
acid derivatives 28a-h were compared with the measured rates of 
racemisation in DMSO-d6 – CD3OD (5:1 v/v).[71] The base in this 
case was 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) present at 
0.5 equivalents. Racemisation was followed by polarimetry and 
rate constants were found to correlate with computed enthalpies 
for proton transfer to either of the two bases at the B3LYP/6-
311+G** level of theory (Figure 5). H/D exchange of more reactive 
substrates was also followed in i-PrOH in the presence of 0.5 
equivalents of trioctylamine, but these data were not correlated 
with computed data. Thioesters were demonstrated to be far more 




Figure 5. Rate constant for racemisation plotted against 
computed enthalpy of deprotonation for compounds 28 (a: R1 = 
Ph, R2 = SEt; b: R1 = CH2Ph, R2 = SEt; c: R1 = CH2Ph, R2 = SEt; 
d: R1 = CH2Ph, R2 = SCH2Ph; e: R1 = CH2CH2Ph, R2 = SEt; f: R1 
= CH2CH2Ph, R2 = SCH2Ph; g: R1 = CH2CH2CH2Me, R2 = SEt; h: 
R1 = CH2CH2CH2Me, R2 = SCH2Ph 
 
An attempted dynamic kinetic resolution of benzoin with lipases 
required rapid racemisation and so solvent combinations were 
investigated, using a zirconium-containing silicate, Zr-TUD-1, as 
a heterogeneous catalyst for racemisation.[72] The addition of 
small amounts of water to solutions in 2-methyltetrahydrofuran 
rapidly diminished the racemization activity whereas the decrease 
was much less marked in toluene.  
A biologically inspired racemization was established for the 
funneling of unwanted R-nornicotine (29) through to racemic 
nornicotine (Scheme 20).[73] This employed pyridoxal (or 
pyridoxal phosphate, a known cofactor, see also Section 4b). 
Attempts to use a smaller mimic for pyridoxal, such as 
formaldehyde, butyraldehyde, benzaldehyde salicylaldehyde and 
4-pyridinecarboxaldehyde all saw no racemization but pyridoxal 
caused racemization to 2.3 % e.e. after 3 hours at 100˙C in pH 
4.5 buffer. This observation suggests that both the pyridine 
nitrogen and adjacent OH are required. Performing the reaction 
in D2O led to deuteration of all of the hydrogens on the pyrrolidine 
ring supporting the rapid formation and isomerization of enamines, 
imines and iminiums. The pH dependence saw the most effective 
reaction at about pH 5. A mechanism was proposed going via the 
intermediacy of an achiral iminium intermediate (Scheme 20). 
 
 






Scheme 20. Racemisation of 29 catalysed by pyridoxal. 
 
Another example of racemization in mixed aqueous systems is 
the synthesis (via dynamic kinetic resolution) of R-bupivacaine, 
30.[74] Ethylene glycol with 10% v/v of water at 138˙C for 9 hours 
was found to give complete racemization. 
The non-steroidal anti-inflammatory drug naproxen has a eutomer 
(the S-enantiomer 31) that is 28 fold more active than the distomer. 
Enzymatic resolution is an attractive option for preparing 31 in a 
stereoselective fashion and therefore racemization protocols 
were sought. A membrane bioreactor was considered in order to 
permit harsh conditions for racemization in a way that would not 
cause degradation of the enzyme.[75] On one side of the 
membrane is an aqueous solution containing enzyme dispersed 
in isooctane and on the other is sodium hydroxide in methanol 
dispersed in isooctane (Figure 6). This bioreactor system was 
able to prepare a single enantiomer of 31 in about 60% yield.  
 
 
Figure 6. Chemical overview of a membrane bioreactor featuring 
racemisation of methyl esters of 31. 
3. Techniques for studying racemisation and 
kinetic data 
 
Typically, the mechanistic studies discussed above were 
supported by kinetic data. We here discuss how such kinetic data 
can be acquired and bring together experimentally determined 
rate constants for racemisation under aqueous conditions. 
 
a) Experimental techniques for studying racemisation 
 
Several techniques have been used to study racemisation and 
developing new techniques has often been a key precursor to new 
discoveries in racemisation.  
 
Nuclear magnetic resonance (NMR) spectroscopy has been a 
popular tool for studying racemisation, particularly for centers of 
type R1R2R3CH that undergo isotopic exchange of hydrogen and 
deuterium.[34,79–84] Mass spectrometry can also be used for this 
type of racemisation.[82] In both cases, the rate of appearance of 
deuterated substrate is monitored and related to the rate of 
racemisation, if the mechanism is well understood. NMR can also 
be used to monitor racemisation by the addition of a chiral shift 
reagent to provide differentiation between enantiomers[53] as 
long as the chiral shift reagent does not affect the racemisation 
reaction. Variable temperature NMR experiments can be used to 
study atropisomerism and racemisation of chiral axes.[22,55] 
 
Circular dichroism (CD) is intrinsically linked to the chirality of 
species being studied. A signal is only present when there is an 
excess of one enantiomer. Thus, the process of racemisation can 
be monitored by the disappearance of a CD signal. The technique 
requires the compound to have a suitable chromophore in the UV-
visible region of the spectrum. This technique can be applied 
without the need for isotopically labelled buffers and therefore 
avoids any solvent kinetic isotope effects induced by the forced 
use of deuterated buffers. Alternatively, the ability to use both 
non-deuterated and fully deuterated buffers provides convenient 
direct access to the solvent kinetic isotope effects. CD has been 
successfully applied to measure the racemisation of several 
systems.[85–87] Analogous to CD spectroscopy, the process of 
racemization can also be monitored using the rotation of plane-
polarized light using polarimeters and measurements such as 
[]D.[57,71] 
 
Chiral chromatographic methods have proved of significant utility 
for studying racemization. This includes gas chromatography for 
studying systems such as nicotine in the vapour phase.[65] Liquid 
chromatographic techniques such as chiral HPLC are used widely 
for studying stereochemistry and racemisation.[33,38,50,88] 
Typical approaches involve either full separation of the 
enantiomers or peak shape analysis for compounds racemising 
in the HPLC eluent.[10,89] A liquid chromatography method has 
been adapted to include an artificial membrane intended to mimic 
cell membranes, an environment that many drugs partition 
into.[90] This was intended to ensure that the measurements 
more closely mimic the in vivo environment. A modified liquid 
chromatographic method saw the use of supercritical liquids.[91]  
 
A triple column technique was developed to study racemisation in 
stopped flow-type conditions.[58] The first column is chiral and 
used to separate enantiomers while the third is also chiral and is 
used to analyse stereoisomers. The second column is achiral and 
is used to expose the compounds to conditions that may promote 
racemisation. This technique was used to study the racemisation 
of 24, which occurs alongside hydrolysis (vide supra). It should be 
noted that on-column racemisation kinetics are typically affected 
by the stationary phase and are not solely representative of the 
kinetics in the HPLC eluent. 
 
Capillary electrophoresis employing chiral modifiers can also be 
used to study racemisation. For example, the use of cyclodextrins 
as chiral modifiers in capillary electrophoresis has been explored 
and used to investigate the racemisation of adrenaline 
(particularly concerned with its use as an additive to local 
anaesthetics).[92] As a further example, on-column racemisation 
capillary electrophoresis employing chiral cyclodextrin additives 
was performed in a quest to find analogues of thalidomide (32) 
that are less likely to racemise but the two molecules considered 






(33 and 34) actually racemised more quickly than thalidomide 




Figure 7. Free energies of activation for racemisation of 32, 33 
and 34.  
 
b) Kinetic data for racemisation of synthetic molecules in 
aqueous conditions 
 
Racemisation has been known about as a problem for synthetic 
molecules when placed in biological media for a long time. It is 
therefore surprising how few relevant measurements have been 
made of the rate of racemisation. We have summarized data of 
sufficient quality in Tables 4 and 5 for compounds racemising via 
general-base catalysis and for compounds racemising via other 
mechanisms, respectively. In Table 4, those compounds that 
likely proceed via the intermediacy of a carbanion have been 
processed to provide a consistent set of second-order rate 
constants kgb for general-base catalysis, where possible. This 
entails considering the protonation state of the molecule that is 
most likely to undergo rapid racemisation (e.g., for compounds 
with a basic amine adjacent to the stereocentre, the base will 
likely be protonated whereas for those with a carboxylic acid, this 
will be neutral). The rate constant is corrected for the 
concentration of this “active” protonation state. The rate constant 
is also corrected for the active component of the buffer and for 
changes in temperature using the Eyring equation in order to 
obtain values for racemisation at 37 °C using ∆‡H° of 22.53 kcal 
mol-1.[34]  
 
The harmonised rate constants collected in Table 4 allowed the 





Table 4. Rate constants measured in aqueous (or predominantly aqueous) conditions for racemisation reactions proceeding via general -base catalysis. 
Compound Ref kmeasured a Mechanism  
(kgb for general-base-catalysed racemisation via 




[80] [phosphate]/M  kdeut (s-1) 
6.7 x 10-4  150 x 10-9 
1.3 x 10-3  2.7 x 10-6 
2.0 x 10-3  3.3 x 10-6 
1.3 x 10-2  31 x 10-6 
6.7 x 10-2  160 x 10-6 
0.133  360 x 10-6 
0.2  650 x 10-6 
 
R1R2R3CH-GBC  
(4.06 x 10-3 M-1s-1) 




[80] [phosphate]/M  kdeut (s-1) 
6.7 x 10-2  47 x 10-6 
0.1  65 x 10-6 
0.133  81 x 10-6 
0.167  98 x 10-6 
0.2  130 x 10-6 
 
R1R2R3CH-GBC  
(8.35 x 10-3 M-1s-1) 




[40] [phosphate]/M  krac (s-1) 
0.04  5.0 x 10-9 
0.02  2.8 x 10-9 
0.004  1.3 x 10-9 
 
R1R2R3CH-GBC  
(7.27 x 10-4 M-1s-1)c 





















[51] k2 = 1.93 x 10-3 M-1s-1 d R1R2R3CH-GBC likely 
(3.72 x 10-2 M-1s-1) d 
H2O, pH 7.4, 37˙C, 25 
mM phosphate buffer 
 
Thalidomide 32 
[93] k2 = 6.6 x 10-3 M-1s-1 R1R2R3CH-GBC  
(8.34 x 10-5 M-1s-1) 
H2O, pH 7.4, 37˙C, 




[34] k2 = 1.4 x 10-5 M-1s-1 R1R2R3CH-GBC  
(1.83 x 10-5 M-1s-1) 
H2O:DMSO 1:1, pH 
7.4, 37˙C, phosphate 






[88] krac = 9.7 x 10-8 s-1 R1R2R3CH-GBC  
(3.33 x 10-5 M-1s-1) d 
H2O:EtOH 9:1, pH 7.4, 
37˙C, 0.05 M 
phosphate buffer  
 
Clopidogrel 38 
[81] [Phosphate]/M  krac (s-1) 
0.1  0.20 x 10-6 
0.2  0.21 x 10-6 
0.3  0.22 x 10-6 
 
R1R2R3CH-GBC  
(2.46 x 10-6 M-1s-1) 
H2O:MeOH 1:1, pH 
7.4, 37˙C, phosphate 






(R=H: 1.64 x 10-5 M-1s-1 
R=p-OH: 6.01 x 10-6 M-1s-1 
R=p-Me: 1.03 x 10-5 M-1s-1 
R=p-F: 2.20 x 10-5 M-1s-1 
R=p-Cl: 7.47 x 10-5 M-1s-1 
R=m-F: 1.40 x 10-4 M-1s-1 
R=m-Cl: 1.60 x 10-4 M-1s-1 
R=p-CF3: 5.15 x 10-4 M-1s-1) 
H2O, pH 7.4, 37˙C, 







(7.87 x 10-6 M-1s-1) 
H2O, pH 7.4, 37˙C, 










(2.74 x 10-3 M-1s-1) 
H2O, pH 7.4, 37˙C, 







(5.62 x 10-5 M-1s-1) 
H2O, pH 7.4, 37˙C, 







(R=phenyl: 7.16 x 10-5 M-1s-1 
R=p-fluorophenyl: 8.92 x 10-5 M-1s-1 
R=p-methoxyphenyl: 5.84 x 10-5 M-1s-1 
R=2-tetrahydrofuranyl: 1.47 x 10-4 M-1s-1 
R=OH: 2.81 x 10-4 M-1s-1 
R=m-pyridyl: 1.23 x 10-4 M-1s-1 
R=2-N-methylpyrrolyl: 7.92 x 10-5 M-1s-1) 
H2O, pH 7.4, 25˙C, 







(R=phenyl: 4.30 x 10-5 M-1s-1 
R=p-fluorophenyl: 3.89 x 10-5 M-1s-1 
R=p-methoxyphenyl: 3.14 x 10-5 M-1s-1 
R=m-pyridyl: 4.19 x 10-4 M-1s-1) 
H2O, pH 7.4, 25˙C, 







(26.9 x 10-3 M-1s-1) 
H2O, pH 7.4, 25˙C, 








[34] krac = 2.56 x 10-3 s-1 R1R2R3CH-GBC  
 
H2O:DMSO 1:1, pH 







(R=H: 2.81 x 10-3 M-1s-1 
R=phenyl: 5.14 x 10-3 M-1s-1 
R=CH2-indolyl: 2.43 x 10-3 M-1s-1 
R=CH2CH2SMe: 9.41 x 10-3 M-1s-1) 
H2O, pH 7.4, 37˙C, 







(7.66 x 10-2 M-1s-1) 
H2O, pH 7.4, 37˙C, 




[96] krac = 4.81 x 10-5 s-1  
(from reported half life of 4 hours) 
R1R2R3CH-GBC  
 
H2O, pH 7.4,  







[96] krac = 6.42 x 10-5 s-1  
(from reported half life of 3 hours) 
R1R2R3CH-GBC  
 
H2O, pH 7.4,  




[96] krac = 7.29 x 10-5 s-1  
(from reported half life of 2.64 hours) 
R1R2R3CH-GBC  
 
H2O, pH 7.4,  
37 °C, 0.01 M 
phosphate buffer 
a. Rate constants are as reported for the indicated reaction conditions. 
b. Rate constants in brackets are extracted second-order kgb for general-base-catalysed racemisation by phosphate via a carbanion at 37˙C. These rate constants have been corrected to 
represent the hypothetical process involving fully protonated substrate, with concentrations corrected to represent only the basic component of the buffer where necessary, and corrected 
for temperature changes using the Eyring equation where necessary. 
c. Rate constant not corrected for temperature but reported as at 25˙C. 
d. Assuming no uncatalysed reaction. 
e. Second-order rate constants were determined explicitly in the original reference. 
 
Table 5. Rate constants measured in aqueous (or predominantly aqueous) conditions for racemisation reactions not proceeding via genera l-base catalysis. 






[31] krac = 4.47 x 10-5 s-1 GAC (imine-enamine tautomerism) H2O, pH 2.5, 37˙C, 








[28] krac = 6.83 x 10-6 s-1 AC (dehydration) H2O, 1.0 M HCl, 30˙C 
 
Allantoin 18 







[45] krac = 3.85 x 10-3 s-1  H2O, pH 7.5, 23˙C, 0.1 
M Tris-HCl buffer 
 
Chlorthalidone 7 
[41] krac = 4.24 x 10-4 s-1 AC (dehydration) 
BC (via ring opening) 





[99] No racemisation observed  H2O, pH 5, 7 and 8.5, 






Mandelic acid 15 




[4] R=CH2OH: 15.5 x 10-6 s-1 
R=CH2OtBu: 10.0 x 10-6 s-1 
R=CH(CH3)OH: 3.98 x 10-6 s-1 
R=CH(CH3)OtBu:  
2.08 x 10-6 s-1 
R=CH2CH2SMe: 3.08 x 10-6 s-1 
R=CH2Ph: 2.35 x 10-6 s-1 
R=CH3: 1.95 x 10-6 s-1 
R=CH(CH3)CO2H:  
4.31 x 10-6 s-1 
R=CH2CO2H: 4.00 x 10-6 s-1 
R=CH2CH(CH3)CO2H:  
1.46 x 10-6 s-1 
R=CH2CH2CO2H:  
1.04 x 10-6 s-1 
R=CH2CH2CH2CO2H:  
0.63 x 10-6 s-1 











4. Biological Racemisation  
a) Racemisation in plasma, serum albumin solutions and in 
the presence of cyclodextrins and liposomes 
 
The racemisation of thalidomide (32) has been studied in a range 
of environments in order to obtain a detailed understanding of the 
toxicity of this most infamous of chiral molecules.[93,100] Studies 
in the 1980s measured the half life for racemisation in pH 7.4 
0.067 M phosphate buffer at 37˙C to be 160 minutes (2.7 
hours),[100,101] in reasonable agreement with the kinetic data by 
Testa et al.[93] In plasma, by contrast, racemisation was 
complete in 2 hours.[100] The racemisation of each enantiomer 
separately was also studied and revealed that in phosphate buffer 
the half life is 260 – 290 minutes whereas in human citrated 
plasma the (+) enantiomer has a half life of 11.5 minutes and the 
(-) enantiomer 8.3 minutes suggesting a more rapid racemisation 
for the (-) enantiomer, as was also the case in rabbit plasma. 
Analogously, in defatted human serum albumin made up in 
phosphate buffer, the (+) enantiomer had a half-life of 18.5 
minutes and the (-) enantiomer 9.5 minutes. Processes may be 
operational in plasma that do not occur in the serum albumin or 
citrated plasma; in both of these media, processes that do not 
occur in buffer alone lead to faster racemisation. For the 
imidazole-containing aromatase inhibitor, 21, there was found to 
be no change in racemisation half life on going from buffer 
solutions to bovine serum albumin solutions.[88] The 
racemisation of thiazolinedione 16 in human plasma and in dog 
plasma was found to occur within minutes.[50] Similarly, 
racemisation of (+)-econazole administered to rats occurs rapidly 
with a half life of 1.24 hours, i.e. approximately two times faster 
than in 0.01 M phosphate buffer.[96] Human serum albumin 
slowed down racemisation of ethiazide and epimerisation of 
etoposide but accelerated epimerisation of carbenicillin,[102] 
showing that serum albumins do not necessarily exert analogous 
effects on all chiral pharmaceuticals. 
 
The effect of adding cyclodextrins on racemisation of 11 was also 
investigated with the expectation that formation of inclusion 
complexes would have a protective effect. The cyclodextrins 
actually exerted a rather mixed effect with -, - and -
cyclodextrin causing faster racemization. Acetylated and 
hydroxypropylated versions of some of the cyclodextrins also had 
the same effect. By contrast, the sulfobutylether-derivatised and 
methylated forms of -cyclodextrin had a protective effect. It was 
speculated that this derivative benefits from electrostatic effects 
that favour formation of the inclusion complex. 
 
Racemisation of 7 was found to be retarded by liposomes.[41] The 
data were analysed in terms of what is essentially a pseudophase 
model[103] showing that racemisation is almost 7-fold slower in 
the liposomes than free in solution.  
 
b) Enzymes to catalyse racemisation 
 
In the vast majority of cases, naturally occurring amino acids are 
found in the L-form. Nevertheless, in certain cases, D-amino acids 
are also found. The strategies used in nature to achieve 
racemisation can shed light on approaches that chemists could 
consider, especially in enzymatic dynamic kinetic resolutions that 
are likely to require racemisation in conditions compatible with the 
enzymes that undertake the chiral resolution. Given that all 
enzymes are themselves chiral, they are unlikely to achieve 
rigorous racemization to a 50:50 mixture of R:S.   
 
The level of D-amino acids for Ser, Ala, Pro, Glu and Asp present 
in proteins in eubacteria (both gram positive and negative), 
archaea and eukaryotes was measured.[104] Most amino acids 
were present in the D configuration at below 1 %. D-Pro was 
present at less than 1 % in all organisms whereas D-Asp was 
present above this level in most of them. D-Ala accounted for 
above 5% of the Ala present in several of the gram-negative 
bacteria and one of these also had above 20 % of D-Glu. D-Glu 
was elevated to 7 % in one of the gram-positive strains that also 
saw 2 % of D-Ser. The results suggest that the tendency to have 
significant concentrations of D-amino acids changed as 
eubacteria evolved towards archaea and eukaryotes. The 
unnatural enantiomer of alanine, D-Ala, is required in the 
construction of the peptidoglycan component of the cell wall of 
bacteria suggesting that an alanine racemase is likely to be 
essential.[105] The absence of a homolog of alanine racemase in 
humans has seen this class of enzymes studied intensely as a 
potential source of a breakthrough in antibacterial research, 
including in drug resistant strains of C. difficile and against strains 
of B. anthracis that are potential biological weapons.[106,107] 
Indeed, S. coelicolor engineered to lack alanine racemase 
required the exogenous addition of D-Ala.  Methods to study the 
racemase activity in S. Lavendulae and E. Coli using circular 
dichroism have been developed.[105,108] However, alternative 
routes for the production of D-Ala take over when alanine 
racemase is mutated in M. smegmatis[109] and in Chlamydia 
pneumonia.[110]  
 
Alanine racemase employs a so-called two-base mechanism in 
which an active site Lys and Tyr are the key catalytic 
residues.[111] Hydrogen kinetic isotope effects (KIE) changing 
the isotope at C as well as the isotope in the solvent were 
measured (Figure 8). These revealed a divergence between 
isotope effects for the two enantiomers; the KIE for D-Ala reduced 
in D2O, whereas that for L-Ala did not and solvent isotope effects 
for the D to L transformation were higher than those for the 
reverse reaction. These differences were interpreted as 
supporting a two-step mechanism through a planar anionic 
intermediate (Scheme 21) that can protonate on either face. If Tyr 
265 is the proton source then L-Ala is formed, whereas if Lys 39 







Figure 8. Hydrogen kinetic isotope effects on reactions catalysed 




The effect of the pyridoxal cofactor on the carbon acidity of glycine 
was studied to understand its effect in the racemase 
enzymes.[112] The pKa of the C in several protonation states of 
the cofactor-glycine conjugate reveal that the most acidic form is 
the one in which both nitrogens, the carboxylic acid and the 
phenol are all protonated (Figure 9).[112] Deprotonation of the 
carboxylic acid and phenol make the C less acidic. However, the 
crystal structure of the enzymes that use pyridoxal are interpreted 
as being best able to stabilise the form in which the carboxylic 
acid and phenol are deprotonated. It is therefore suggested that 
it is this form that is the key intermediate in these reactions. 
QM/MM studies (AM1 parameterised to reproduce higher levels 
of theory was used for the QM part) using phenol as a model for 
a key catalytic site tyrosine suggest that the pKa for deprotonation 
of alanine at C is lowered by about 22 units by the presence of 
the pyridoxal and its surroundings.[113] Further computational 
studies investigated the reaction of alanine racemase in gas 
phase, water, with PLP in its unprotonated and protonated form 
and in the enzyme.[114] These calculations (Table 6) suggested 
that enzyme catalysis arises from approximately equal 
contributions from the co-factor and interactions with the enzyme.  
 
Figure 9. Acidity of the C proton in a range of protonation states 
of the glycine complex with pyridoxal. 
 
Table 6. Computed and experimental free energy barriers to the 
uncatalysed, pyridoxal- and alanine racemase-catalysed 
racemisations of alanine. 
System ∆G‡(computed) ∆G‡(experiment)[111,115] 








26.3 kcal/mol >25 kcal/mol 
Alanine 
Racemase 
18.6 kcal/mol 12.8 kcal/mol 
 
Serine racemase is active in human and other mammals and its 
product, D-Ser, plays a role in neurotransmission and 
memory.[116] Like alanine racemase, it employs a pyridoxal co-
factor. QM/MM methods employing AM1 parameterised to 
reproduce DFT energetics and geometries were used to study the 
action of this racemase, which acts in a dimeric form (Table 7). A 
steered molecular dynamics simulation followed the reaction 
coordinate for racemisation and revealed barriers in excellent 
agreement with experiment. These support the co-factor being 
present in its non-protonated form and the reaction proceeding in 
a way that sees the hybridisation of C go from sp3 to sp2 and 
back again, in line with an intermediate carbanion. The residues 
responsible for protonating each of the two faces are Lys 56 and 
Ser 84. These play roles in Serine racemase that are analogous 
to those for Lys39 and Tyr 265 in Alanine racemase, shown in 
Scheme 21. 
 
Table 7. Computed and experimental free energy barriers to the 




L-Ser to D-Ser 20.7 kcal/mol 19.1 kcal/mol 
D-Ser to L-Ser 17.4 kcal/mol 18.3 kcal/mol 
 
Racemase (epimerase) enzymes that do not require pyridoxal 




tuberculosis and proline racemase.[118] It was found (via 
mutation and chemical transformation) that there are two key 
cysteine residues responsible for the stereochemical scrambling 
in these enzymes (Scheme 22). A computational study 
investigated the mechanism of action of proline racemase as well 
as the process that operates in aqueous solution.[119] QM/MM 
calculations using AM1 parameterised to reproduce higher levels 
of theory suggested that neither the uncatalysed nor catalysed 
reaction involve a stable anionic intermediate because the barrier 
to reprotonation is negligible. The catalytic effect of the enzyme 
amounts to 14 kcal/mol of barrier lowering thanks to a tight 
network of hydrogen bonds that are poised to stabilise the 
transition state of the reaction. Neighbouring residues stabilise 
the system during movement of the negative charge from one Cys 
thiolate to another. A definitive explanation for the surprising 





The antibiotic molecule D-cycloserine is produced by several 
strains of Streptomyces. A key step in its formation is 
stereochemical inversion, likely in intermediate 53, and a putative 
enzyme for this (DcsC) was identified and isolated (Scheme 
23).[120] It was surprising that the KM and kcat values for the L to 
D process (110 mM and 158 s-1) differed significantly from those 
for the D to L process (17 mM and 29 s-1). A double base thiol-
thiolate mechanism was supported by the observation of 
irreversible inhibition by an epoxide (54) and by site-directed 




In order to understand the action of mandelate racemase, which 
racemises mandelic acid, the uncatalyzed reaction in aqueous 
buffers was studied alongside reactions with a range of additives 
that support active site glutamate and histidine residues acting in 
their protonated forms (Figure 10).[122]  
 
 
Figure 10. Proposed active site protonation states for mandelate 
racemase. 
 
c) Racemisation (or epimerisation) of proteins and amino 
acids 
 
The uncatalysed racemisation of amino acids is generally very 
slow and this can be a useful feature to facilitate the dating of 
proteinaceous material.[4,5] Consequently, the influence of the 
sidechain on the rate of racemization is worth understanding.[4] 
These studies support the cyclization of acidic sidechains to yield 
readily racemising lactams (see below). The alcohols in serine 
and threonine elevate rate constants by being both electron 
withdrawing and hydrogen bond donors (interacting with base, 
water or terminal carboxylates). The tert-butyl ethers of Ser and 
Thr have lower rate constants for racemisation supporting the 
hydrogen bonding effect; these ethers are in turn faster 
racemising than Ala, supporting the importance of the electron-
withdrawing oxygen. The increased rate constant for Met may 
also be caused by a through-space interaction; thioethers have 
been shown to be able to act like weak hydrogen bond donors, 
albeit with strict geometrical restrictions.[123] Phe has a higher 
rate constant for racemisation than Ala due to the inductive effect 
of the aromatic ring. 
 
Computational studies predicting the free energy of deprotonation 
of amino acids and substituted amino acids using B3LYP/6-
311G** and the IEFPCM solvation model achieved a good 
correlation with measured rate constants (Figure 11).[124] The 
authors recommend the use of gas phase calculations because 
the addition of the IEFPCM solvation did not improve the 
correlation but did slow down the calculations. A special 
mechanism for racemisation of aspartic acid and asparagine 
residues has been proposed that proceeds via succinimide 
intermediates (Scheme 24).[125] The proposed succinimide 
intermediate 55 is computed to be 13 kcal/mol more acidic than 
the open chain structure. This mechanism also suggests that the 
formation of D-Asp could be from L-Asn, rather than L-Asp. 
Recent results have suggested that anionic intermediates that 
have the possibility of aromatic character can enhance 
racemisation liability and it is noteworthy that the keto-enol 
tautomer of 55 would fall into this category.[85] Other studies 
have cast doubt on the relevance of cyclic species favouring a 






Figure 11. Computed deprotonation energies plotted against rate 





Stereochemical scrambling of the amino acids in proteins has also 
been proposed as a method to validate the origin of various 
natural compounds.[127] For instance, being able to prove the 
source of balsamic vinegars is important to prevent counterfeit 
products reaching the market, particularly those that circumvent 
the expensive aging process. In this context, racemisation of 
proline to form D-Pro is particularly prominent in vinegars. The 
percentage of D-amino acid was measured over time under 
heating in both red wine vinegar and aqueous acetic acid giving 
the rate constants shown in Table 8; Pro was found to be slowly 
racemizing. An enzyme-mediated process by residual microbial 
racemases was suggested to explain this. Racemisation in the 
presence of sugars (glucose and fructose are present in balsamic 
vinegars) was also observed, presumably via Schiff base 
formation and this too might explain the rapid racemisation of Pro, 
which, uniquely among the amino acids, can form an iminium that 
cannot shed a proton to become a neutral imine. 
 
Table 8. Rate constants for racemisation in red wine vinegar and 
aqueous acetic acid. 
Amino acid krac x 10-7 (s-1) in 
red wine vinegar, 
pH 2.5, 100 °C 
krac x 10-7 (s-1) in 
5 % AcOH, pH 2.5, 
100 °C 
Asp 40.28 32.64 
Ser 8.89 7.94 
Ala 5.14 1.81 
Phe 4.44 1.58 
Lys 3.47 1.53 
Met 3.47 1.39 
Tyr 3.06 1.11 
Glu 2.92 0.83 
Pro 2.78 0.69 
Leu 1.67 0.42 
Val 0.69 0.01 
 
d) Derivatives and prodrugs 
 
One of the complexities of racemisation in a biological context is 
that the process can proceed through the transient formation of 
biological conjugates or metabolites. For instance, the profen 
drugs (including ibuprofen) are known to undergo racemization in 
vivo.[128–132] For these compounds, which have a eutomer with 
the S configuration, racemisation occurs via formation of the Acyl 
CoA thioesters in which the stabilising carboxylate is transformed 
into a destabilising thioester group (see below). The thioester can 
be rapidly hydrolysed to recover the acid after the stereochemical 
scrambling. Direct racemisation of ibuprofen could only be 
achieved under non-biological conditions of high pH and 
temperature.[133]  
 
Some medications are provided as prodrugs, which are 
molecules that are not themselves active but are transformed into 
active drugs. For prodrugs, it is possible that racemisation occurs 
in either the prodrug or the drug. One example is clopidogrel (38, 
Table 4), which is provided as a methyl ester that is hydrolysed in 
vivo to a carboxylic acid. [134] This in turn can be transformed 
into acyl CoA thioesters. All of these possibilities were considered 
in studies of the racemisation of clopidogrel in which hydrolysis 
was monitored and for which the possibility of conjugates was 
considered via the addition of hepatocytes.[81] In vivo studies in 
rat supported the acid being the predominant species present in 
circulation and that about 4 to 8 % of this is R enantiomer after 
dosing the S enantiomer. None of the in vitro studies were able to 
rationalise this finding. 
 
Similarly, in a prodrug, the chirality may not reside in the active 
drug as in the case of valaciclovir, 56. Compound 56 is absorbed 
by the body more readily than acyclovir, 57, and is swiftly broken 
down into L-valine and acyclovir by esterases in the 
body.[135,136] Compound 56 was selected from a series of 18 
amino acid ester prodrugs. The prodrugs were administered to 
rats and the amount of the active metabolite 57 in their urine was 
determined. It was determined that L-56 gave the highest amount 
of excreted 57. The D- and rac- forms were also tested and gave 
a lower amount of excreted 57. The authors suggested that this is 







5. Tools to understand and predict 
racemisation rates.  
 
It will have been noted by the attentive reader that the chemical 
diversity of the compounds for which the rate of aqueous 
racemisation has been measured is rather limited. For this reason, 




have used the chemical agnosticism of quantum mechanics to 
provide methods to predict the likely impact of racemisation. 
 
The stability of carbanions in various molecular structures in 
aqueous environments is relevant to many biological reactions 
including decarboxylations and has been studied by the Richard 
group over the course of several years.[138–147] These studies 
provide a host of experimental measurements relating to the pKa 
of carbon acids and rationales for these observed acidities. Many 
of the groups stabilise the carbanion by resonance, notably the 
adjacent carbonyl (58), nitrile and aromatic groups (Figure 
12).[140] The effect of a range of carbonyl types on the pKa of the 
carbanions was summarised (Table 9).[143,146] The differing 
effects of these groups were rationalised by a combination of 
electron-withdrawing character and a π-donor (or acceptor) effect. 
A reversed amide also stabilises carbanions, as assessed by the 
reduction in pKa from 18.7 to 14.5 when adding such a group 
alpha to a ketone (Figure 13, top).[138,143,148] It was proposed 
that this occurs via the resonance forms shown and is helped by 
a through-space electrostatic interaction between the anion and 
the polarized NH bond. An electrostatic effect can be achieved by 
an adjacent basic amine group (Figure 13, bottom left).[138,144] 
This change also increased the rate of deuteration 3500-fold for 
N-protonated glycine methyl ester compared to the rate for ethyl 
acetate.[139] An imine group has an even larger effect on pKa 
than protonated amines giving a very large (7 log unit) decrease 
from 21 to 14.[143,146] The opposite electrostatic effect is in 
operation for acidic groups such as carboxylates (Figure 13, 
bottom right) and this leads these to be stabilising groups, 
reflected in their impact on carbanion pKa values (Table 





Figure 12. The resonance stabilisation of carbanions leading to 
increased acidity. 
Table 9. pKa values for methyl substituted carbonyls (58) 












Figure 13. The carbon acid pKas of a range of carbonyl-
containing compounds. 
 
The distance dependence of the electrostatic acceleration is 
emphasised by the contrast between the deuteration rates of 59 
and 60 (Figure 14).[144] The cyclic 59 exchanges 500 times more 
slowly than 60 because the positive charged pyridinium would be 
in closer proximity to the anion in 60. 
 
Figure 14. pKa and deprotonation rates of two pyridinium-
substituted ketones with similar pKas. 
 
A predictive method of assessing racemisation resulted from a 
series of papers from the Université de Lausanne. These papers 
describe studies of the rate of racemisation of a range of 
compounds in aqueous media and led to a summary of the 
structure-racemisation relationships for the general-base 
mediated reaction.[149,150] For compounds of type R1R2R3CH to 
racemise, there should be two or three of the groups that 
decrease stability of the chiral center, shown in Table 10. These 
can be combined only with neutral groups, the presence of any of 
the groups that increase stability is sufficient to remove the risk of 
racemisation. It can be seen that the groups that decrease 
stability of the stereogenic centre do so by stabilising an adjacent 
negative charge either by delocalisation or by induction and those 
that increase stability of a stereogenic centre destabilise adjacent 
negative charges. This approach provides a very simple non-
quantitative but useful initial guide to identifying racemisation risk. 
 
Table 10. Groups identified by Testa as increasing or decreasing 
the stability of an adjacent stereogenic carbon. From Ref. [149] 
 
Decrease stability Neutral Increase stability 
Ester Alkyl Carboxylate 
Aryl ketone  Sulfate 
Amide   
Hydroxyl   
Amine   
N-linked imine   
Halogens   
Pseudohalogens   
Aromatic groups   
Benzyl groups   





Computational studies have also been applied to understand and 
predict racemisation. One of the rare examples of a stereogenic 
centre in drug molecules that is not a tetrahedral carbon is in 
proton pump inhibitors such as omeprazole, 61. Calculations 
using RHF theory suggested that the barrier for this compound to 
invert via planarization at sulfur would be 43 kcal/mol which would 
make it highly unlikely to racemise.[151] Semiempirical AM1 
calculations were used to understand the racemisation in 
acetonitrile of two chiral ketones, 62 and 63.[152] The 
aforementioned studies by Servi and co-workers and by Zeng and 
co-workers correlate the rate constants for racemisation of amino 
acids with experimental rate constants.[71,124] However, these 
computational studies provide correlations strictly within 
compound classes. 
 
Computational studies have also been prominent for 
understanding the racemisation of chiral axes. The work of a 
group at Boehringer-Ingelheim defined many of the key ideas, 
including the classification of compounds into those that rotate so 
quickly that rapid equilibration will always occur, those that are so 
slow that enantiomers would be separable and stable and finally, 
those in the middle that are likely to require more care. 
Compounds with barriers at the HF/6-31G** level below ~20 
kcal/mol or above ~30 kcal/mol can be developed as single 
compounds whereas those in between these two extremes are 
likely to form mixtures with a time dependence that is comparable 
to storage and dosing of drugs.[15] Variations on this approach 
have been described subsequently.[22,55] 
 
A quantitative approach to rates of general-base-catalysed 
racemisation across compound classes was recently described in 
which two computational and two practical methods complement 
one another to provide differing levels of speed and throughput 
and different levels of accuracy.[85] Measurements of the rate of 
racemisation exploited NMR spectroscopy to follow deuterium 
incorporation or circular dichroism to follow racemisation directly. 
These techniques were used to expand the available set of 
racemisation rate constants. One computational approach 
considers the contribution of groups adjacent to a carbanion to its 
stability, this technique can be rapidly applied to sets of many 
compounds. An alternative uses quantum mechanics to compute 
the energy of deprotonation (at the B3LYP/6-31+G* level 
including IEFPCM solvation). In both cases, the deprotonation 
energy is correlated with measured second-order rate constants 
(Figure 15) to create a linear free energy relationship (LFER). This 
LFER permits these rate constants to be predicted from purely 
computational data. An estimate of the concentration of active 
basic components of phosphate buffer that is equivalent to that in 
blood permits the amount of racemisation to be expected in vivo 
in any given time period to be estimated. A subset of compounds 
were found to follow a different trend in the group contribution 
approach – those that feature an anionic intermediate that could 
be thought of as aromatic and such molecules have an enhanced 
rate of racemisation. 
 
 
Figure 15. Top) Plot of logarithms of the second-order rate 
constants for general-base-catalysed racemisation (logkgb) in 
aqueous conditions plotted against deprotonation free energy 
computed computed using quantum mechanical calculations and 
Bottom) Plot of logkgb against the sum of group contributions to 
anion stabilisation with compounds that involve an aromatic anion 
in blue squares and those that do not as red diamonds.  
These approaches suggest that there is a strong relationship 
between the stability of a carbanion and liability towards 
racemization, as expected for a mechanism involving rate-
determining deprotonation. 
 
The correlation provided by this LFER finally provides a 
quantitative prediction of racemisation risk across compound 
classes. 
6. Summary and Outlook 
There is a strong awareness of the importance of chirality in 
biomolecular recognition and this has led to a steady interest in 
the process of racemisation. Nevertheless, kinetic and 
mechanistic studies of racemisation processes under relevant 
conditions have been few and sets of kinetic data are rarely 
sufficient for unambiguous mechanistic interpretation. This review 
summarises kinetic data and its interpretation for a series of 
compounds for which racemisation has been studied. The review 
also links such chemical studies with the analogous processes 









G(R1,R2,R3) / kcal mol-1













occurring in biological systems. Probably as a result of limited 
good quality experimental data, until recently models predicting 
racemisation risk were limited to individual compound classes, but 
this situation has now changed. We hope that this review will 
further stimulate the renaissance of kinetic and mechanistic 
studies in this important area so that our understanding and future 
predictive models can be further improved. 
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Although the importance of 
racemisation is well known, the 
process remains poorly studied.  In 
this review, the available data 
concerning chemical (acid and base) 
and enzymatic catalysis of 
racemisation and predictive tools are 
presented and discussed. The paucity 
of relevant data is striking. 
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